Skip to main content
. 2013 Oct 14;8(10):e77240. doi: 10.1371/journal.pone.0077240

Table 3. Overall and progression-free survival according to tumor factors in subgroups.

Population Median OS (95% CI) (months)
Hazard Ratio (95% CI) for S-LRTs (vs. S-M) P
S-M S-LRTs
Entire cohort 5.5 (4.7–6.2) 8.5 (6.2–10.7) 0.5 (0.4–0.7) 0.001
Subgroup with neither EHS nor RNI 7.8 (6.2–9.3) 18.0 (3.7–33.2) 0.4 (0.2–0.9) 0.019
Subgroup with EHS and/or RNI 4.8 (3.7–5.8) 8.3 (5.0–11.5) 0.6 (0.4–0.9) 0.028
Subgroup with AFP <400 ng/mL 7.8 (6.6–8.9) 8.3 (5.2–11.3) 0.8 (0.5–1.3) 0.449
Subgroup with AFP ≥400 ng/mL 3.4 (2.5–4.2) 8.0 (0.0–19.0) 0.3 (0.1–0.6) 0.001
Population Median PFS (95% CI) (months)
Hazard Ratio (95% CI) for S-LRTs (vs. S-M) P
S-M S-LRTs
Entire cohort 3.0 (2.7–3.2) 5.3 (4.0–6.5) 0.6 (0.4–0.8) 0.002
Subgroup with neither EHS nor RNI 3.2 (1.8–4.5) 9.6 (3.1–16.0) 0.5 (0.2–0.9) 0.027
Subgroup with EHS and/or RNI 2.9 (2.5–3.2) 4.9 (4.0–5.7) 0.7 (0.4–1.0) 0.069
Subgroup with AFP <400 ng/mL 4.0 (2.6–5.3) 6.8 (4.1–9.4) 0.7 (0.4–1.1) 0.225
Subgroup with AFP ≥400 ng/mL 2.0 (1.6–2.3) 4.2 (2.6–5.7) 0.5 (0.3–0.8) 0.012

Abbreviations: OS, overall survival; PFS, progression-free survival; CI, confidence interval; S-M, sorafenib monotherapy; S-LRTs, sorafenib combined with loco-regional treatments; EHS, extrahepatic spread; RNI, regional nodal involvement.